{"id":"https://openalex.org/W1147720358","doi":"https://doi.org/10.1182/blood.v122.21.2106.2106","title":"Brentuximab Vedotin Administered To Platinum-Refractory Transplant Na\u00efve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status","display_name":"Brentuximab Vedotin Administered To Platinum-Refractory Transplant Na\u00efve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W1147720358","doi":"https://doi.org/10.1182/blood.v122.21.2106.2106","mag":"1147720358"},"language":"en","primary_location":{"id":"mag:1147720358","doi":"https://doi.org/10.1182/blood.v122.21.2106.2106","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/122/21/2106/11885/Brentuximab-Vedotin-Administered-To-Platinum","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070783771","display_name":"Maika Onishi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maika Onishi","raw_affiliation_strings":["Dept. of Medicine, University of Washington, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Medicine, University of Washington, Seattle, WA, USA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010023051","display_name":"Leona Holmberg","orcid":"https://orcid.org/0000-0003-3277-1910","observed_orcids":["https://orcid.org/0000-0003-3277-1910","https://orcid.org/0000-0002-2803-0469"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leona Holmberg","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0003-3277-1910","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059661907","display_name":"Andrei R. Shustov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrei R. Shustov","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066264510","display_name":"Karen Schiavo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Schiavo","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center , Seattle, WA , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center , Seattle, WA , USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038579280","display_name":"Arnp Arnp","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arnp Arnp","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center , Seattle, WA , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center , Seattle, WA , USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049229364","display_name":"Mary Philip","orcid":"https://orcid.org/0000-0001-7496-2630","observed_orcids":["https://orcid.org/0000-0001-7496-2630"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Philip","raw_affiliation_strings":["Dept. of Medicine, University of Washington, Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0001-7496-2630","affiliations":[{"raw_affiliation_string":"Dept. of Medicine, University of Washington, Seattle, WA, USA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084492085","display_name":"Edward N. Libby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward N. Libby","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071844603","display_name":"Ryan Daniel Cassaday","orcid":"https://orcid.org/0000-0002-3424-2425","observed_orcids":["https://orcid.org/0000-0002-3424-2425"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan D. Cassaday","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0002-3424-2425","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040412322","display_name":"John M. Pagel","orcid":"https://orcid.org/0000-0001-5745-8125","observed_orcids":["https://orcid.org/0000-0001-5745-8125","https://orcid.org/0000-0003-2875-4878"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Pagel","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0001-5745-8125","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016684714","display_name":"David G. Maloney","orcid":"https://orcid.org/0000-0002-8477-6919","observed_orcids":["https://orcid.org/0000-0002-8477-6919"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David G. Maloney","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0002-8477-6919","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007024434","display_name":"Damian J. Green","orcid":"https://orcid.org/0000-0003-0477-1446","observed_orcids":["https://orcid.org/0000-0003-0477-1446"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Damian J. Green","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0003-0477-1446","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037938194","display_name":"Brian G. Till","orcid":"https://orcid.org/0000-0002-4718-8288","observed_orcids":["https://orcid.org/0000-0002-4718-8288"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian G. Till","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0002-4718-8288","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023180146","display_name":"Oliver W. Press","orcid":"https://orcid.org/0000-0002-3147-8037","observed_orcids":["https://orcid.org/0000-0002-3147-8037"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Oliver W. Press","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0002-3147-8037","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center,\u00a0Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay K. Gopal","raw_affiliation_strings":["University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"],"raw_orcid":"https://orcid.org/0000-0003-3023-6834","affiliations":[{"raw_affiliation_string":"University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.6774,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.68529804,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"122","issue":"21","first_page":"2106","last_page":"2106"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":0.9020000100135803},{"id":"https://openalex.org/keywords/hodgkin-lymphoma","display_name":"Hodgkin's disease","score":0.8640000224113464},{"id":"https://openalex.org/keywords/platinum-refractory-disease","display_name":"platinum-refractory disease","score":0.8309999704360962},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.8820000290870667},{"id":"https://openalex.org/keywords/salvage-chemotherapy","display_name":"salvage chemotherapy","score":0.7480000257492065},{"id":"https://openalex.org/keywords/cd30","display_name":"CD30","score":0.8460000157356262},{"id":"https://openalex.org/keywords/monomethyl-auristatin-e","display_name":"monomethyl auristatin E","score":0.859000027179718},{"id":"https://openalex.org/keywords/relapsed-hodgkin-lymphoma","display_name":"relapsed Hodgkin lymphoma","score":0.6499999761581421},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6579999923706055},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6000000238418579},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.37400001287460327},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.4180000126361847},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.41200000047683716}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8296854496002197},{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.8070270419120789},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.6668057441711426},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5507062077522278},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5285683274269104},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4146583378314972},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4142794609069824},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.35171520709991455},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34682968258857727},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.31770551204681396},{"id":"https://openalex.org/C70905583","wikidata":"https://www.wikidata.org/wiki/Q3648608","display_name":"CD30","level":3,"score":0.25579363107681274}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:1147720358","doi":"https://doi.org/10.1182/blood.v122.21.2106.2106","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/122/21/2106/11885/Brentuximab-Vedotin-Administered-To-Platinum","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2168543296","https://openalex.org/W150670019","https://openalex.org/W4296468576","https://openalex.org/W4406678445","https://openalex.org/W2111070506","https://openalex.org/W2056942759","https://openalex.org/W2586677173","https://openalex.org/W2751395693","https://openalex.org/W2884911346","https://openalex.org/W4251787242"],"abstract_inverted_index":{"Background":[0],"Classical":[2],"Hodgkin":[3],"lymphoma":[4],"(HL)":[5],"is":[6,13,27,79,95,111],"characterized":[7],"by":[8,37],"CD30-positive":[9,220],"Reed-Sternberg":[10],"cells":[11],"and":[12,41,114,184,192,229,267,269,281,304,313,319,337,358,373,380,415,438,542,549,561,578,583,605,613,640,668],"frequently":[14],"curable":[15],"with":[16,33,49,65,117,140,157,167,208,284,309,392,492,610],"initial":[17],"therapy.":[18,216],"The":[19,234,293,361,402,510,569],"standard":[20,459],"treatment":[21],"for":[22,649],"relapsed":[23,122,168,341],"or":[24,169,474,657],"refractory":[25,170,335],"HL":[26,123,159,171,286,638],"multi-agent":[28],"salvage":[29,77,134,215,227,345,647,680],"chemotherapy,":[30],"most":[31],"commonly":[32],"platinum-based":[34,214,344,364],"regimens":[35,406],"followed":[36],"high":[38],"dose":[39,460,575],"chemoradiotherapy":[40],"autologous":[42],"stem":[43],"cell":[44],"transplantation":[45],"(ASCT)":[46],"in":[47,121,136,150,155,196,258,377,427,431,435,440,487,608,630],"patients":[48,139,156,218,278,308,324,332,339,385,468,499,525,533,546,558,563,609,639,650],"chemosensitive":[50],"disease.":[51,342],"Normalization":[52],"of":[53,131,148,186,237,243,307,397,405,443,447,461,497,520,524,545,555,576,633],"fluorodeoxyglucose-positron":[54],"emission":[55],"tomography":[56],"(FDG-PET)":[57],"imaging":[58],"prior":[59,92,160,408,421],"to":[60,93,104,161,245,255,263,265,363,409,419,453,500,528,566,591,597,664],"ASCT":[61,94,579],"has":[62],"been":[63],"associated":[64],"improved":[66],"outcomes":[67,677],"(Moskowitz":[68,81],"AJ":[69],"et":[70,83],"al.,":[71,84],"2010)":[72],"even":[73],"when":[74],"a":[75,88,100,112,205,209,393,470,508,626,643],"second":[76],"therapy":[78,116,135,257,346,365,599],"employed":[80],"CH":[82],"2012).":[85],"Thus,":[86],"achieving":[87,151],"FDG-PET":[89,152,212,247,501,587,627],"negative":[90,153,502,588,628],"state":[91],"desirable.":[96],"Brentuximab":[97],"vedotin":[98],"(BV),":[99],"CD30-directed":[101],"antibody":[102],"linked":[103],"the":[105,129,146,174,225,241,289,305,416,458,518,531,553,573,595,674],"antitubulin":[106],"agent":[107],"monomethyl":[108],"auristatin":[109],"E,":[110],"safe":[113],"well-tolerated":[115],"favorable":[118],"response":[119,207,254,362,368,418,512,596],"rates":[120,590],"post-ASCT.":[124],"Limited":[125],"data":[126,329,620],"exist":[127],"regarding":[128],"use":[130],"BV":[132,149,223,244,259,410,449,483,493,577,592,623],"as":[133,678],"transplant":[137,635],"naive":[138,636],"persistently":[141,210],"positive":[142],"FDG-PET.":[143],"We":[144,275],"evaluated":[145],"role":[147],"status":[154],"platinum-refractory":[158,285,498,637],"ASCT.":[162],"Methods":[164],"Patients":[166],"treated":[172],"at":[173,296,457,654],"Fred":[175],"Hutchinson":[176],"Cancer":[177,181],"Research":[178,688,691,694,697,700,714,726],"Center,":[179],"Seattle":[180],"Care":[182],"Alliance,":[183],"University":[185],"Washington":[187],"Medical":[188],"Center":[189],"between":[190],"2009":[191],"2013":[193],"were":[194,316,559,564,600],"included":[195,251,347],"this":[197,238],"retrospective":[198],"analysis":[199],"if":[200,670],"they":[201],"achieved":[202,507,547,653],"less":[203],"than":[204],"complete":[206,424],"abnormal":[211],"following":[213,224],"All":[217,384],"had":[219,230,333,340,386,469,526],"tumors,":[221],"received":[222,407],"failed":[226],"regimen":[228],"follow-up":[231,571],"functional":[232],"imaging.":[233],"primary":[235,334],"endpoint":[236],"study":[239],"was":[240,298,366,411,423,455,484,514,580],"ability":[242,262],"normalize":[246],"scans.":[248],"Secondary":[249],"endpoints":[250],"disease":[252,315,336,371,375,389],"response,":[253],"subsequent":[256],"failures,":[260],"toxicity,":[261],"proceed":[264],"ASCT,":[266],"survival":[268],"progression-free":[270],"status.":[271],"Results":[273],"identified":[276],"15":[277],"(10":[279],"male":[280],"5":[282],"female)":[283],"who":[287,651],"met":[288],"above":[290],"inclusion":[291],"criteria.":[292],"median":[294,394,403,446,570],"age":[295],"diagnosis":[297],"30.8":[299],"years":[300],"(range,":[301,413,451],"17-":[302],"64)":[303],"numbers":[306],"stage":[310],"II,":[311],"III,":[312],"IV":[314],"6,":[317],"4,":[318],"2":[320,452,467,473],"patients,":[321,382],"respectively.":[322,383,551,586,615],"3":[323,381,465],"did":[325],"not":[326,485],"have":[327,652],"staging":[328],"available.":[330],"11":[331],"4":[338,448],"Qualifying":[343],"ICE/RICE":[348],"(10);":[349],"bendamustine,":[350],"etoposide,":[351],"carboplatin":[352],"(2);":[353,357],"gemcitibine,":[354],"carboplatin,":[355],"dexamethasone":[356],"DHAP":[359],"(1).":[360],"partial":[367],"(PR),":[369],"stable":[370],"(SD),":[372],"progressive":[374],"(PD),":[376],"3,":[378],"9,":[379],"residual":[387],"FDG-avid":[388],"on":[390,400,594],"PET":[391],"maximum":[395],"bulk":[396],"12.8":[398],"cm":[399],"CT.":[401],"number":[404],"2.5":[412],"2-4),":[414],"best":[417],"any":[420],"chemotherapy":[422],"remission":[425],"(CR)":[426],"13%":[428,441],"(2/15),":[429],"PR":[430],"33%":[432],"(5/15),":[433],"SD":[434,656],"40%":[436],"(6/15),":[437],"PD":[439],"(2/15)":[442],"patients.":[444],"A":[445],"cycles":[450],"7)":[454],"administered":[456],"1.8":[462],"mg/m2":[463],"every":[464],"weeks.":[466],"documented":[471,565],"grade":[472],"higher":[475],"adverse":[476],"event":[477],"(peripheral":[478],"neuropathy,":[479],"allergic":[480],"reaction),":[481],"but":[482],"discontinued":[486],"either":[488],"patient.":[489],"Treatment":[491],"converted":[494],"47%":[495],"(7/15)":[496],"status,":[503],"while":[504],"7%":[505],"(1/15)":[506],"PR.":[509],"overall":[511],"rate":[513],"53%":[515],"(8/15).":[516],"At":[517,552],"time":[519,554],"analysis,":[521,556],"87%":[522],"(13/15)":[523],"proceeded":[527],"HDT/ASCT.":[529],"For":[530],"8":[532,562],"whose":[534],"post-ASCT":[535,676],"restaging":[536],"scans":[537],"are":[538,662],"available,":[539],"50%":[540],"(4/8)":[541],"12.5%":[543],"(1/8)":[544],"CR":[548,589,629],"PR,":[550,611],"14/15":[557],"alive":[560],"be":[567,642],"progression-free.":[568],"since":[572],"last":[574],"485":[581],"days":[582],"491":[584],"days,":[585],"based":[593],"platinum":[598],"67%":[601],"(2/3),":[602],"56%":[603],"(5/9),":[604],"0%":[606],"(0/3)":[607],"SD,":[612],"PD,":[614],"Conclusion":[617],"Our":[619],"suggest":[621],"that":[622],"can":[624],"induce":[625],"approximately":[631],"half":[632],"all":[634],"may":[641],"particularly":[644],"effective":[645],"second-line":[646],"strategy":[648],"least":[655],"better.":[658],"Further":[659],"prospective":[660],"studies":[661],"needed":[663],"confirm":[665],"these":[666],"findings":[667],"determine":[669],"BV-induced":[671],"CRs":[672],"predict":[673],"same":[675],"conventional":[679],"regimens.":[681],"Disclosures:":[683],"Holmberg:Seattle":[685],"Genetics:":[686,711,717,723],"Consultancy,":[687,712,724],"Funding;":[689,692,695,698,701],"Millennium:":[690],"Merck:":[693],"Otsuka:":[696],"Sanofi:":[699],"Educational":[702],"Concepts:":[703],"Speakers":[704,728,731],"Bureau;":[705,729],"Allos:":[706],"Consultancy;":[707],"Genzyme:":[708],"Consultancy.":[709,721],"Shustov:Seattle":[710],"Honoraria,":[713,725],"Funding.":[715],"Pagel:Seattle":[716],"Equity":[718],"Ownership.":[719],"Press:Roche/Genentech:":[720],"Gopal:Seattle":[722],"Funding,":[727],"Millenium:":[730],"Bureau.":[732]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}